Stock Price
4.13
Daily Change
2.23%
Yearly
-41.58%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Brainstorm Cell Therapeutics 3.33 -0.15 -4.31% -42.29%
Bioline Rx 2.22 -0.10 -4.31% -4.31%
Cerulean Pharma 1.78 0.09 5.33% 18.67%
Celldex Therapeutics 35.68 -1.93 -5.13% 81.95%
Clovis Oncology 2.76 -0.35 -11.25% -47.92%
Eleven Biotherapeutics 0.91 -0.10 -9.61% -40.33%
Immunogen 6.62 -0.54 -7.54% 9.97%
Incyte Corp 65.78 -0.85 -1.28% -20.88%
Merrimack Pharmaceuticals 4.13 0.09 2.23% -41.58%
Lumos Pharma Inc. 7.15 -0.21 -2.85% -55.37%
Roche Holding 362.25 -1.20 -0.33% 19.85%
Sanofi 47.07 -0.62 -1.30% -7.76%

Indexes Price Day Year
US2000 2159 -47.02 -2.13% 14.10%
NASDAQ 15085 -295.85 -1.92% 21.03%

Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.